Literature DB >> 24222840

Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry.

Alvaro Alonso1, Joel M Gore, Hamza H Awad, Ann L Quill, Gilles Montalescot, Frans van de Werf, Dietrich C Gulba, Keith A A Fox, Kim A Eagle, Christopher B Granger, Allison Wyman, Ph Gabriel Steg.   

Abstract

AIMS: To describe the characteristics, treatment, and mortality in patients with ST-elevation myocardial infarction (STEMI) by use of chronic oral anticoagulant (OAC) therapy.
METHODS: Using data from the Global Registry of Acute Coronary Syndromes (GRACE), patient characteristics, treatment, and reperfusion strategies of STEMI patients on chronic OAC are described, and relevant variables compared with patients not on chronic OAC. Six-month post-discharge mortality rates were evaluated by Cox proportional hazard models.
RESULTS: Of 19,094 patients with STEMI, 574 (3.0%) were on chronic OAC at admission. Compared with OAC non-users, OAC users were older (mean age 73 vs. 65 years), more likely to be female (37 vs. 29%), were more likely to have a history of atrial fibrillation, prosthetic heart valve, venous thromboembolism, or stroke/transient ischaemic attack, had a higher mean GRACE risk score (166 vs. 145), were less likely to be Killip class I (68 vs. 82%), and were less likely to undergo catheterization/percutaneous coronary intervention (52 vs. 66%, respectively). Of the patients who underwent catheterization, fewer OAC users had the procedure done within 24 h of admission (56.5 vs. 64.5% of OAC non-users). In propensity-matched analyses (n=606), rates of in-hospital major bleeding and in-hospital and 6-month post-discharge mortality were similar for OAC users and OAC non-users (2.7 and 3.7%, p=0.64; 15 and 13%, p=0.56; 15 and 12%, p=0.47, respectively), rates of in-hospital recurrent myocardial infarction (8.6 and 2.0%, p<0.001) and atrial fibrillation (32 and 22%, p=0.004) were higher in OAC patients, and rates of 6-month stroke were lower (0.6 and 4.3%, p=0.038). Patients in both groups who underwent catheterization had lower mortality than those who did not undergo catheterization.
CONCLUSIONS: This is the largest study to describe the characteristics and treatment of STEMI patients on chronic OAC. The findings suggest that patients on chronic OAC are less likely to receive guideline-indicated management, but have similar adjusted rates of in-hospital and 6-month mortality.

Entities:  

Keywords:  Acute coronary syndrome; anticoagulant; guidelines; myocardial infarction

Mesh:

Substances:

Year:  2013        PMID: 24222840      PMCID: PMC3821815          DOI: 10.1177/2048872613483019

Source DB:  PubMed          Journal:  Eur Heart J Acute Cardiovasc Care        ISSN: 2048-8726


  38 in total

1.  Can warfarin randomized trials be reproduced in 'real life'? Adherence to warfarin guidelines for intensity of anticoagulation in a university-based warfarin clinic.

Authors:  A K Malik; A J Taylor
Journal:  South Med J       Date:  2000-01       Impact factor: 0.954

2.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

Authors:  S R Mehta; S Yusuf; R J Peters; M E Bertrand; B S Lewis; M K Natarajan; K Malmberg; H Rupprecht; F Zhao; S Chrolavicius; I Copland; K A Fox
Journal:  Lancet       Date:  2001-08-18       Impact factor: 79.321

3.  Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.

Authors:  E J Topol
Journal:  Lancet       Date:  2001-06-16       Impact factor: 79.321

4.  Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.

Authors: 
Journal:  Lancet       Date:  2001-08-25       Impact factor: 79.321

5.  Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes.

Authors: 
Journal:  Am Heart J       Date:  2001-02       Impact factor: 4.749

6.  Acute coronary syndromes in patients with prior cerebrovascular events: lessons from the Euro-Heart Survey of Acute Coronary Syndromes.

Authors:  David Hasdai; Moti Haim; Solomon Behar; Valentina Boyko; Alexander Battler
Journal:  Am Heart J       Date:  2003-11       Impact factor: 4.749

7.  Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.

Authors:  Rikke Sørensen; Morten L Hansen; Steen Z Abildstrom; Anders Hvelplund; Charlotte Andersson; Casper Jørgensen; Jan K Madsen; Peter R Hansen; Lars Køber; Christian Torp-Pedersen; Gunnar H Gislason
Journal:  Lancet       Date:  2009-12-12       Impact factor: 79.321

8.  Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.

Authors:  Stephen G Ellis; Paul Armstrong; Amadeo Betriu; Bruce Brodie; Howard Herrmann; Gilles Montalescot; Franz-Josef Neumann; John J Smith; Eric Topol
Journal:  Am Heart J       Date:  2004-04       Impact factor: 4.749

9.  A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.

Authors:  Kim A Eagle; Michael J Lim; Omar H Dabbous; Karen S Pieper; Robert J Goldberg; Frans Van de Werf; Shaun G Goodman; Christopher B Granger; P Gabriel Steg; Joel M Gore; Andrzej Budaj; Alvaro Avezum; Marcus D Flather; Keith A A Fox
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

10.  Acute coronary syndromes in patients with pre-existing moderate to severe valvular disease of the heart: lessons from the Euro-Heart Survey of acute coronary syndromes.

Authors:  David Hasdai; Eli I Lev; Solomon Behar; Valentina Boyko; Nicholas Danchin; Alec Vahanian; Alexander Battler
Journal:  Eur Heart J       Date:  2003-04       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.